- Title
- Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone
- Creator
- Lee, Chee Khoon; Gebski, Val J.; Coates, Alan S.; Veillard, Anne-Sophie; Harvey, Vernon; Tattersall, Martin H. N.; Byrne, Michael J.; Brigham, Brian; Forbes, John; Simes, R. John
- Relation
- SpringerPlus Vol. 2
- Publisher Link
- http://dx.doi.org/10.1186/2193-1801-2-391
- Publisher
- SpringerOpen
- Resource Type
- journal article
- Date
- 2013
- Description
- Background: We evaluate trade-offs between quality of life (QoL) and survival improvement for two chemotherapy regimens in advanced breast cancer. We also report on the long-term survival of patients in the ANZ 8614 clinical trial. Methods: A total of 391 patients were randomized to mitoxantrone (14 mg/m² intravenously every 21 days) or a combination of cyclophosphamide 100 mg/m² and prednisone 40 mg/m² orally days 1 to 14 plus methotrexate 40 mg/m² and 5-fluorouracil 600 mg/m² intravenously days 1 and 8 every 28 days (CMFP). QoL was self-assessed on 14 linear analog scales. We computed the mean differences between the two treatments as products of the mean differences in global QoL, progression-free survival and overall survival. Results: CMFP led to a higher overall tumor response (39% vs. 25%, P=0.004) and longer progression-free survival (PFS) (median 5.6 vs 3.9 months, P=0.02) but with significantly more toxicity from alopecia, mucositis, diarrhea, anemia and lethargy. Overall survival (OS) was similar in the two groups (median 10.1 vs 11.6 months, P=0.81). QoL over the first 12 weeks was rated better by patients on CMFP for mood (P=0.04), nausea and vomiting (P=0.01), and feeling sick (P=0.02) but worse for hair loss (P<0.0001). A weighted combination of individual QoL items favoured CMFP (subset score mean difference 2.4, P=0.03). A global QoL score tended to favour CMFP (global score mean difference 1.7, P=0.18). Quality-adjusted PFS was significantly longer with CMFP (mean 7.208 vs 5.965 months, P=0.04), but quality-adjusted OS was not significantly different (mean 11.832 vs 11.315 months, P=0.57). Conclusion: Despite the greater toxicity, the superior antitumor activity of CMFP led to an overall improvement in quality-adjusted PFS. In advanced breast cancer, in clinical decision making about treatment for palliative intent, the principle used to assess trade-offs between antitumor efficacy and toxicity remains relevant and applicable to all modern therapeutic agents.
- Subject
- breast cancer; chemotherapy; quality of life; toxicity; survival; randomized trial
- Identifier
- http://hdl.handle.net/1959.13/1062875
- Identifier
- uon:17161
- Identifier
- ISSN:2193-1801
- Language
- eng
- Full Text
- Reviewed
- Hits: 22743
- Visitors: 7751
- Downloads: 360
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT01 | Publisher version (open access) | 401 KB | Adobe Acrobat PDF | View Details Download |